These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 16005367

  • 1. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
    Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, Nam MS, Lee KW.
    Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
    [Abstract] [Full Text] [Related]

  • 2. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Aug; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 3. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T, Matsuda T, Suzuki Y, Ueda Y, Koide H.
    ASAIO J; 2003 Aug; 49(4):430-4. PubMed ID: 12918586
    [Abstract] [Full Text] [Related]

  • 4. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Aug; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 5. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
    Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL.
    Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
    [Abstract] [Full Text] [Related]

  • 6. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF.
    Endothelium; 2006 May; 13(3):227-31. PubMed ID: 16840178
    [Abstract] [Full Text] [Related]

  • 7. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
    Chen R, Zhang AR, Zhao XX, Li ZH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
    [Abstract] [Full Text] [Related]

  • 8. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [Abstract] [Full Text] [Related]

  • 9. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [Abstract] [Full Text] [Related]

  • 10. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 11. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S, Melandri G, Hanemaaijer R, Cervi V, Tomasi L, Altimari A, Van Lent N, Tricoci P, Bacchi L, Branzi A.
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [Abstract] [Full Text] [Related]

  • 12. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B, Urban M.
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [Abstract] [Full Text] [Related]

  • 13. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 14. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
    Am Heart J; 2005 Sep 02; 150(3):484-7. PubMed ID: 16169329
    [Abstract] [Full Text] [Related]

  • 15. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE.
    Clin Biochem; 2009 Jul 02; 42(10-11):984-90. PubMed ID: 19358835
    [Abstract] [Full Text] [Related]

  • 16. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.
    El Messal M, Beaudeux JL, Drissi A, Giral P, Chater R, Bruckert E, Adlouni A, Chapman MJ.
    Clin Chim Acta; 2006 Apr 02; 366(1-2):185-9. PubMed ID: 16280123
    [Abstract] [Full Text] [Related]

  • 17. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 May 02; 403(1-2):173-7. PubMed ID: 19254704
    [Abstract] [Full Text] [Related]

  • 18. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2005 Mar 02; 18(3):325-9. PubMed ID: 15797648
    [Abstract] [Full Text] [Related]

  • 19. Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy.
    Sampson M, Wall S, Baugh M, Worley J, Davies I, Hughes D, Gavrilovic J.
    Diabetes Res Clin Pract; 2006 Jan 02; 71(1):45-51. PubMed ID: 16023759
    [Abstract] [Full Text] [Related]

  • 20. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W.
    Int J Obes (Lond); 2008 May 02; 32(5):763-71. PubMed ID: 18197181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.